Testing of Nebulizers for Delivering Magnesium Sulfate to Pediatric Asthma Patients in the Emergency Department

References

1. 1.↵
   1. Scarfone RJ,
   2. Fuchs SM,
   3. Nager AL,
   4. Shane SA

   . Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993;92(4):513–518.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Becker A,
   2. Lemière C,
   3. Bérubé D,
   4. Boulet LP,
   5. Ducharme FM,
   6. FitzGerald M,
   7. Kovesi T

   ; Asthma Guidelines Working Group of the Canadian Network For Asthma Care. Summary of recommendations from the Canadian asthma consensus guidelines, 2003. CMAJ Can Med Assoc J 2005;173(6 Suppl):S3–S11.

   OpenUrl
3. 3.↵
   1. Kercsmar CM,
   2. McDowell KM

   . Love it or lev it: levalbuterol for severe acute asthma: for now, leave it. J Pediatrics 2009;155(2):162–164.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Fischl MA,
   2. Pitchenik A,
   3. Gardner LB

   . An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med 1981;305(14):783–789.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Weiss KB,
   2. Sullivan SD,
   3. Lyttle CS

   . Trends in the cost of illness for asthma in the United States, 1985–1994. J Allergy Clin Immunol 2000;106(3):493–499.

   OpenUrlCrossRefPubMedWeb of Science
6. 6.↵
   1. Mohammed S,
   2. Goodacre S

   . Intravenous and nebulised magnesium sulphate for acute asthma: systematc review and meta-analysis. Emerg Med J 2007;24(12):832–830.

   OpenUrl
7. 7.↵
   1. Cheuk DK,
   2. Chau TC,
   3. Lee SL

   . A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child 2005;90(1):74–77.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Aggarwal P,
   2. Sharad S,
   3. Handa R,
   4. Dwiwedi SN,
   5. Irshad M

   . Comparison of nebulised magnesium sulfate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study. Emerg Med J 2006;23(5):358–362.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Schuh S,
   2. Macias C,
   3. Freedman S,
   4. Plint A,
   5. Zorc J,
   6. Baja JL,
   7. et al

   . North American practice patterns of IV magnesium therapy in severe acute asthma in children. Acad Emerg Med 2010;17(11):1189–1196.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Okayama H,
    2. Aikawa T,
    3. Okayama M,
    4. Sasaki H,
    5. Mue S,
    6. Takishima T

    . Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. JAMA 1987;257(8):1076–1078.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Blitz M,
    2. Blitz S,
    3. Beasely R,
    4. Diner BM,
    5. Hughes R,
    6. Knopp JA,
    7. Rowe BH

    . Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev 2005;(4):CD003898.
12. 12.↵
    1. Villeneuve EJ,
    2. Zed PJ

    . Nebulized magnesium sulfate in the management of acute exacerbations of asthma. Ann Pharmacother 2006;40(6):1118–1124.

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Dodd ME,
    2. Abbott J,
    3. Maddison J,
    4. Moorcroft AJ,
    5. Webb AK

    . Effect of tonicity of nebulized colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52(7):656–658.

    OpenUrlAbstract
14. 14.↵
    1. Ho SL,
    2. Kwong WTJ,
    3. Coates AL

    . Evaluation of four breath-enhanced nebulizers for home use. J Aerosol Med 2001(4):14:467–475.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Katz SL,
    2. Adatia I,
    3. Louca E,
    4. Leung K,
    5. Humpl T,
    6. Reyes JT,
    7. Coates AL

    . Nebulized therapy for childhood pulmonary hypertension: an in vitro model. Pediatr Pulmonol 2006;41(7):666–673.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. O'Callaghan C,
    2. Clarke AR,
    3. Milner AD

    . Inaccurate calculation of drug output from nebulisers. Eur J Pediatr 1989;148(5):473–474.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Lands LC,
    4. Smountas A,
    5. Meisner D,
    6. Kelemen S,
    7. Vadas EB

    . Factors influencing the rate of drug output during the course of wet nebulization. J Aerosol Med 1998;11(2):101–111.

    OpenUrl
18. 18.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Allen PD,
    4. Ho SL,
    5. Lands LC

    . Do sinusoidal models of respiration accurately reflect the respiratory events of cystic fibrosis patients breathing on nebulizers? J Aerosol Med 1999;12(4):265–273.

    OpenUrlPubMed
19. 19.↵
    1. Leung K,
    2. Louca E,
    3. Coates AL

    . Comparison of breath enhanced to breath actuated nebulizers for rate, consistency, and efficiency. Chest 2004;126(5):1619–1627.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Coates AL,
    2. Tipples G,
    3. Leung K,
    4. Gray M,
    5. Louca E

    ; WHO Product Development Group for Measles Aerosol Vaccine. How many infective particles are necessary for successful mass measles immunization by aerosol? Vaccine 2006;24(10):1578–1585.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Mitchell JP,
    2. Nagel MW,
    3. Nichols S,
    4. Nerbrink O

    . Laser diffractometry as a technique for rapid assessment of aerosol particle size from inhalers. J Aerosol Med 2006;19(4):409–433.

    OpenUrlPubMed
22. 22.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Meisner D,
    4. Kelemen S,
    5. Thibert R,
    6. MacDonald J,
    7. Vadas EB

    . The choice of jet nebulizer, nebulizing flow and the addition of Ventolin respiratory solution affects tobramycin aerosols used in cystic fibrosis. Chest 1997;111(5):1206–1212.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.
    1. MacNeish CF,
    2. Meisner D,
    3. Thibert R,
    4. Kelemen S,
    5. Vadas EB,
    6. Coates AL

    . A comparison of pulmonary availability between Ventolin (albuterol) nebules and Ventolin (albuterol) respirator solution. Chest 1997;111(1):204–208.

    OpenUrlCrossRefPubMedWeb of Science
24. 24.
    1. Newman SP,
    2. Pellow PG,
    3. Clay MM,
    4. Clarke SW

    . Evaluation of jet nebulisers for use with gentamycin solution. Thorax 1985;40(9):671–676.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Clay MM,
    2. Pavia D,
    3. Newman SP,
    4. Clarke SW

    . Factors influencing the size distribution of aerosols from jet nebulisers. Thorax 1983;38(10):755–759.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Janssens HM,
    2. de Jongste JC,
    3. Fokkens WJ,
    4. Robben SG,
    5. Wouters K,
    6. Tiddens HA

    . The Sophia anatomical infant nose-throat (SAINT) model: a valuable tool to study aerosol deposition in infants. J Aerosol Med 2001;14(4):433–441.

    OpenUrlPubMed
27. 27.↵
    1. Ciarallo L,
    2. Brousseau D,
    3. Reinert S

    . Higher dose intravenous magnesium sulfate therapy for children with moderate to severe acute asthma. Arch Pediatr Adolesc Med 2000;154(10):979–983.

    OpenUrlCrossRefPubMedWeb of Science
28. 28.↵
    1. Coates AL,
    2. MacNeish CF,
    3. Dinh L,
    4. Rollin T,
    5. Gagnon S,
    6. Ho SL,
    7. Lands LC

    . Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. J Aerosol Med 2000;13(3):169–178.

    OpenUrlPubMedWeb of Science
29. 29.↵
    1. Coates AL,
    2. Green M,
    3. Leung K,
    4. Louca E,
    5. Tservistas M,
    6. Chan J,
    7. et al

    . The challenges of quantitative measurement of lung deposition using ^99mTc-DTPA from delivery systems with very different delivery times. J Aerosol Med 2007;20(3):320–330.

    OpenUrlCrossRefPubMed